Tetracyclic Compounds as SMARCA2 and/or SMARCA4 Degraders

3:

• The compound of claim 1, wherein,
• L1 is a bond, phenylenyl or 4- to 6-membered heterocycloalkylenyl;
• wherein phenylenyl and heterocycloalkylenyl, at each occurrence, independently is substituted with 0, 1, 2, 3 or 4 of R7;
• L2 is —CH2— or 4- to 6-membered heterocycloalkylenyl substituted with 0, 1, 2, 3 or 4 of R7;
• and
• L3 is a bond, alkylenyl or 4- to 6-membered heterocycloalkylenyl;
• wherein the alkylenyl, and the heterocycloalkylenyl, at each occurrence, is substituted with 0, 1, 2, 3 or 4 of R7.

4:

• The compound of claim 1, wherein Q is represented by formula Q1:
• wherein
• R4 is hydrogen or (C1-C6)alkyl;
• R5 is hydrogen;
• and
• R6 and R6′ independently is hydrogen;
• or R6 and R6′ together represent an oxo group.

5:

• The compound of claim 1, wherein Q is represented by formula Q2:
• wherein
• X is a bond, O, —(CO)—NH— or NH;
• X1 is N or CH;
• R5 is hydrogen or halogen;
• and
• R4 is hydrogen or (C1-C6)alkyl.

6:

• The compound of claim 1, wherein Q is represented by formula Q3:
• wherein,
• R4 is hydrogen or (C1-C6)alkyl;
• R5 is hydrogen or halogen;
• each Z1 and Z6 is independently C, CH or N;
• and
• each Z2, Z3 Z4 and Z5 is independently C, CH or N.

16:

• The compound claim 8,
• wherein
• R1 and R3 independently is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, amino, cyclopropyl, cyclobutyl, cyclopentyl or hydroxy;
• R2 is hydrogen, halogen, hydroxy, (C1-C6)alkyl or 3- to 8-membered cycloalkyl;
• L1 is a bond, phenylenyl or 4- to 6-membered heterocycloalkylenyl;
• L2 is —CH2— or 4- to 6-membered heterocycloalkylenyl;
• L3 is a bond, alkylenyl or 4- to 6-membered heterocycloalkylenyl;
• Q is selected from
• wherein each R4 is (C1-C6)alkyl or hydrogen;
• and each R5 is (C1-C6)alkyl or hydrogen.

17:

• The compound of claim 1, having the compound of formula (IB):
• wherein Y1 and Y2 independently is CH or N;
• L1 is a bond, phenylenyl or heterocycloalkylenyl;
• and
• L3 is a bond, alkylenyl or heterocycloalkylenyl.

22:

• The compound of claim 17, wherein
• A is phenyl or pyridyl;
• each R1 is halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, amino or hydroxy;
• Y1 and Y2 independently is CH or N;
• R2 is hydrogen, halogen, hydroxy, (C1-C6)alkyl or 3- to 8-membered cycloalkyl;
• L1 is a bond or a group selected from
• L3 is a bond or a group selected from —CH2—, —CH2—CH2—, —CH(CH3)—CH2—,
• Q represents
• and
• ‘n’ is an integer selected from 0, 1 and 2.

25:

• The compound of claim 23, wherein Y1 and Y2 independently is CH or N;
• L3 is selected from —CH2, —CH2CH2—,
• R1 is selected from —Br, —Cl, —NH2, —CH3, —OCH3, —OH and —CF3;
• R2 is hydrogen, —CH3, —CH(CH3)2, cyclopropyl, cyclobutyl or cyclopentyl;
• and
• represents

28:

• The compound of claim 26, wherein
• Y1 and Y2 independently is CH or N;
• L3 is selected from —CH2, —CH2CH2—,
• R1 is selected from —Br, —Cl, —NH2, —CH3, —OCH3, —OH and —CF3;
• R2 is hydrogen, —CH3, —CH(CH3)2, cyclopropyl, cyclobutyl or cyclopentyl;
• and
• represents

29:

• The compound of claim 1, is selected from:
• Compound
• No.
• Structure
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• and
• 50
• or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

38:

• The method of claim 37, wherein the disease or disorder dependent upon SMARCA2 and/or SMARCA4 is cancer, selected from hematologic cancers, lung cancer, non-small cell lung cancer, acoustic neuroma, acute leukemia, acute lymphocytic acute myelocytic leukemia, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic, acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic, granulocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes, dysplasias and metaplasias, embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, head and neck cancer, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, liver cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, malignant rhabdoid tumor (MRT), rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors, carcinomas, sarcomas, small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer or Wilms' tumor.